Related references
Note: Only part of the references are listed.The Culture of Trial Results Reporting at Academic Medical Centers
Deborah A. Zarin
JAMA INTERNAL MEDICINE (2020)
Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA
Ramtin Talebi et al.
TRIALS (2020)
Understanding current practice, identifying barriers and exploring priorities for adverse event analysis in randomised controlled trials: an online, cross-sectional survey of statisticians from academia and industry
Rachel Phillips et al.
BMJ OPEN (2020)
Is it time for computable evidence synthesis?
Adam G. Dunn et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2020)
Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
Joshua D. Wallach et al.
BMC MEDICINE (2019)
Association Between Data Sources and US Food and Drug Administration Drug Safety Communications
Noam Tau et al.
JAMA INTERNAL MEDICINE (2019)
10-Year Update on Study Results Submitted to ClinicalTrials.gov
Deborah A. Zarin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis
Chris A. Rees et al.
PLOS MEDICINE (2019)
Comparison of Data on Serious Adverse Events and Mortality in ClinicalTrials.gov, Corresponding Journal Articles, and FDA Medical Reviews: Cross-Sectional Analysis
Richeek Pradhan et al.
DRUG SAFETY (2018)
Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010
Nicholas S. Downing et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Update on Trial Registration 11 Years after the ICMJE Policy Was Established
Deborah A. Zarin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials
Lisa M. Schwartz et al.
ANNALS OF INTERNAL MEDICINE (2016)
Trial Reporting in ClinicalTrials.gov - The Final Rule
Deborah A. Zarin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles
Eve Tang et al.
BMC MEDICINE (2015)
Compliance with Results Reporting at ClinicalTrials.gov
Monique L. Anderson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Reporting Discrepancies Between the ClinicalTrials.gov Results Database and Peer-Reviewed Publications
Daniel M. Hartung et al.
ANNALS OF INTERNAL MEDICINE (2014)
Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection
Rong Xu et al.
BMC BIOINFORMATICS (2014)
Era Of Faster FDA Drug Approval Has Also Seen Increased Black-Box Warnings And Market Withdrawals
Cassie Frank et al.
HEALTH AFFAIRS (2014)
Reporting of Results in ClinicalTrials.gov and High-Impact Journals
Jessica E. Becker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Non-publication and delayed publication of randomized trials on vaccines: survey
Lamberto Manzoli et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
The Future of Population-Based Postmarket Drug Risk Assessment: A Regulator's Perspective
T. A. Hammad et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System
R. Harpaz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
The Practice of Pre-Marketing Safety Assessment in Drug Development
Christy Chuang-Stein et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2013)
Haphazard reporting of deaths in clinical trials: a review of cases of ClinicalTrials.gov records and matched publications-a cross-sectional study
Amy Earley et al.
BMJ OPEN (2013)
Timing and Completeness of Trial Results Posted at ClinicalTrials.gov and Published in Journals
Carolina Riveros et al.
PLOS MEDICINE (2013)
A Lifecycle Approach to the Evaluation of FDA Approval Methods and Regulatory Actions Opportunities Provided by a New IOM Report
Bruce M. Psaty et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
The rise and fall of rosiglitazone
Steven E. Nissen
EUROPEAN HEART JOURNAL (2010)
Reporting of Safety Results in Published Reports of Randomized Controlled Trials
Isabelle Pitrou et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
The New Sentinel Network - Improving the Evidence of Medical-Product Safety
Richard Platt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis
Joseph S. Ross et al.
PLOS MEDICINE (2009)
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Kerry Dwan et al.
PLOS ONE (2008)
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
P Juni et al.
LANCET (2004)
Better reporting of harms in randomized trials: An extension of the CONSORT statement
JPA Ioannidis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Share Paper
